Olfr798 is a member of the olfactory receptor (OR) family, which is integral to the olfactory system. As a G protein-coupled receptor (GPCR), it plays a crucial role in detecting and responding to specific odorant molecules. The activation of olfactory receptors like Olfr798 typically involves the binding of these odorant molecules, which induces a conformational change in the receptor. This change facilitates the interaction with G proteins, subsequently triggering a cascade of intracellular signaling events that lead to the perception of odors. The specific ligands and the full range of physiological functions of Olfr798 are not completely understood, as is often the case with ORs due to their highly specific and diverse ligand affinities. The mechanism of Olfr798 activation, as with other GPCRs, is influenced by various factors within the cell. A significant regulatory pathway in GPCR function involves cyclic adenosine monophosphate (cAMP). As a secondary messenger, cAMP is involved in regulating a wide array of cellular functions, including GPCR signaling. The synthesis of cAMP is catalyzed by adenylate cyclase, which converts ATP into cAMP in response to external stimuli. The accumulation of cAMP can activate protein kinase A (PKA), resulting in the phosphorylation of different proteins, including GPCRs. This phosphorylation can affect the receptor's sensitivity to its ligands and its overall responsiveness. Moreover, cAMP can interact with other signaling pathways that converge with GPCR signaling, thus indirectly influencing the activity of receptors such as Olfr798.
Phosphodiesterases (PDEs), which degrade cAMP, play a vital role in regulating its intracellular levels. Inhibiting PDEs can lead to an increase in cAMP within the cell, indirectly affecting GPCR signaling. This increase in cAMP, caused by PDE inhibition, can indirectly modulate the activity of Olfr798 through various mechanisms, including changes in receptor phosphorylation, ligand-receptor interactions, and receptor-G protein coupling. Additionally, compounds that directly increase cAMP levels, such as adenylate cyclase activators or β-adrenergic receptor agonists, can also indirectly influence the activity of Olfr798. These interactions demonstrate the complexity of GPCR regulation and highlight the potential of various chemical compounds to modulate the activity of receptors like Olfr798 indirectly. In conclusion, understanding the activation of Olfr798 is crucial for comprehending the olfactory system and the broader role of GPCRs in sensory perception and physiological processes. The complex interplay between different cellular components and signaling molecules, as well as the potential for modulation by external compounds, underscores the complexity and significance of studying these receptors.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a synthetic catecholamine and β-adrenergic agonist, elevates intracellular cAMP through adenylate cyclase activation. This cAMP increase could indirectly modulate Olfr798 signaling pathways, enhancing receptor activation and signal transduction. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels, potentially influencing Olfr798 indirectly by modulating GPCR signaling pathways, altering receptor dynamics, and enhancing signaling efficacy. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, an endogenous catecholamine, stimulates α and β-adrenergic receptors to increase cAMP via adenylate cyclase. This surge in cAMP could indirectly affect Olfr798 activation, potentially enhancing its activity through downstream signaling cascades. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), leading to increased cAMP levels. Elevated cAMP may enhance Olfr798 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics, and impacting downstream signaling. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide, a selective PDE3 inhibitor, raises intracellular cAMP, potentially influencing Olfr798 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol, a β2-adrenergic agonist, increases cAMP levels via adenylate cyclase activation. This rise might boost Olfr798 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. Elevated cAMP might stimulate Olfr798 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors, increasing cAMP. This elevation could modulate Olfr798 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr798 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy. | ||||||